CC
IOVA icon

Carlson Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Carlson Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-108,280
Closed -$493K – 138
2023
Q3 		$493K Buy
108,280
+3,806
+4% +$24.8K 0.04% 123
2023
Q2 		$735K Sell
104,474
-77,635
-43% -$556K 0.06% 105
2023
Q1 		$1.11M Hold
182,109
– – 0.1% 97
2022
Q4 		$1.16M Buy
182,109
+7,109
+4% +$55.5K 0.09% 102
2022
Q3 		$1.68M Buy
175,000
+25,000
+17% +$288K 0.13% 99
2022
Q2 		$1.66M Buy
150,000
+50,000
+50% +$655K 0.11% 106
2022
Q1 		$1.67M Buy
+100,000
New +$1.55M 0.11% 131

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Carlson Capital's IOVA Position: Q4 2023 in Review

Carlson Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 108,280 shares — an estimated $493K sold.

Carlson Capital first reported a position in IOVA in Q1 2022 and held it in 7 quarters. The position peaked at $1.68M in Q3 2022. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • Carlson Capital reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Carlson Capital sold 108,280 Iovance Biotherapeutics shares in Q4 2023, an estimated $493K.
  • Carlson Capital first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 7 quarters.
  • Carlson Capital's Iovance Biotherapeutics position peaked at $1.68M in Q3 2022.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on Carlson Capital's 13F filing for Q4 2023, filed 13 Feb 2024.